BYVALSON
Clinical safety rating
cautionComprehensive clinical and safety monograph for BYVALSON (BYVALSON).
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
| Metabolism | Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive. |
| Excretion | Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h |
| Half-life | Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours) |
| Protein binding | 95% bound primarily to albumin |
| Volume of Distribution | Vd 8-10 L/kg; suggests extensive extravascular distribution |
| Bioavailability | Oral: 50% (range 40-60%); food reduces peak concentration but not AUC |
| Onset of Action | Oral: 2-4 hours to peak effect; maximal antihypertensive effect within 2-4 weeks |
| Duration of Action | 24 hours with once-daily dosing; steady-state achieved by 7 days; gradual offset over 48-72 hours |
| Molecular Weight | 435.5 |
160 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function. |
| 1st trimester | Contraindicated due to risk of teratogenicity (neural tube defects, cardiovascular anomalies) based on animal studies and human data from other ACE inhibitors. |
| 2nd trimester | Contraindicated due to risk of fetal renal impairment, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. |
| 3rd trimester | Contraindicated due to risk of fetal renal impairment, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. |
Clinical note
Comprehensive clinical and safety monograph for BYVALSON (BYVALSON).
| Placental transfer | Extensive placental transfer demonstrated in human studies; crosses placenta and is present in fetal tissues. |
| Breastfeeding | Excreted in breast milk in low concentrations; however, due to potential for severe neonatal adverse effects (hypotension, renal impairment), use is not recommended during breastfeeding. Alternative agents should be considered. |
| Lactation Rating | L5 |
| Teratogenic Risk | Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and serum potassium. Fetal monitoring includes ultrasound assessment for oligohydramnios, fetal growth, and amniotic fluid index. Neonates should be observed for hypotension, hyperkalemia, and renal dysfunction. |
| Fertility Effects | ARBs may impair fertility by affecting the renin-angiotensin system; animal studies show reduced fertility with valsartan. Nebivolol may affect male fertility via β-blockade. Clinical significance in humans is unclear. |
■ FDA Black Box Warning
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
| Serious Effects |
Hypersensitivity to valsartan or any componentPregnancyHistory of angioedema with ACE inhibitors or ARBsConcomitant use with aliskiren in patients with diabetes mellitusSevere hepatic impairment (Child-Pugh C)Biliary cirrhosisCholestasis
| Precautions | Hypotension in volume- or salt-depleted patients, Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics, Renal function impairment, including acute renal failure, Angioedema (rare), Use caution in severe aortic stenosis, Avoid concomitant use with aliskiren in diabetic patients |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels. |
| Clinical Pearls | BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFrEF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated. |
| Patient Advice | Do not take within 36 hours of any ACE inhibitor medication. · Take BYVALSON twice daily with or without food. · Monitor blood pressure regularly; report dizziness or fainting. · Avoid salt substitutes containing potassium. · Seek medical help immediately if you experience swelling of the face, lips, or throat. · Stay hydrated but do not use potassium supplements without consulting your doctor. |
Loading safety data…